BRAF and metastatic melanoma: Malignancies that are caused by v-Rapidly accelerated fibrosarcoma viral oncogene homolog B1 (BRAF) mutations, such as metastatic melanoma, can potentially be treated with BRAF inhibitors, such as vemurafenib and dabrafenib.